"Cash flow positive!" -- three little words that are music to biotech investors' ears.
I'm not sure if investors are quite as excited about "adjusted EBIDTA positive." It just doesn't have the same ring to it. Not to mention that earnings before interest, depreciation, taxes, and appreciation doesn't mean nearly as much as seeing the greenbacks in the bank account.
For now, though, that's all Elan's
Elan is basically a one-trick pony at this point. Its share of Tysabri sales, which Elan splits with Biogen Idec
At that point, it'll basically be Tysabri and the pipeline of Alzheimer's drugs. While the potential for both is huge, Elan is going to have to operate flawlessly on Tysabri to convince patients that the benefits from taking the drug outweigh the risk.
For the Alzheimer's drugs, the company just needs to get lucky. The disease has taken down many a drug -- Eli Lilly's
Elan is headed in the right direction, but investors should be cautious here. Elan needs more than a little cash flow to justify the $3 billion market cap.
Interested in keeping track of Elan as it moves toward making money for investors? Click here to add it to My Watchlist, which will help you keep track of all our Foolish analysis on Elan.
Elan is a Motley Fool Rule Breakers pick. Pfizer is a Motley Fool Inside Value recommendation. Motley Fool Options has recommended a diagonal call position on Johnson & Johnson, which is a Motley Fool Income Investor selection. The Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days.
Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool has a disclosure policy.